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Dear Editor,
Please find enclosed a manuscript entitled “Babesia species present in Ixodes ricinus ticks and 
clinical/serological outcome in humans after an infected tick bite in Sweden and the Åland 
Islands”.
I and my co-authors would be very pleased if you would consider this manuscript for publication 
as a Research article in the journal Ticks and Tick-borne Diseases.
Babesiosis is a tick-borne human infection in the temperate regions of North America and 
Eurasia. In many European countries, cases of babesiosis are not mandatorily notifiable by 
medical practitioners. Therefore, the number of babesiosis cases are unknown. The risk of 
developing a Babesia infection after a single tick bite is also unknown but depends likely on 
many factors such as developmental stage of the tick, duration of tick feeding, the Babesia 
species to be transmitted as well as the number of Babesia parasites in the tick and possible co-
infection with other tick-borne pathogens.
In an effort to elucidate the incidence of babesiosis and to investigate how different factors 
influence the risk of developing a Babesia infection, we collected and analyzed ticks for the 
presence of Babesia spp. that had been found attached to people in Sweden and Åland Islands 
(Finland). At the time of the tick bite and three months later, we collected and analyzed blood 
samples for the presence of anti-Babesia antibodies from the tick-bitten people. In order to 
determine if participants were diagnosed with babesiosis within the three-month study period, 
medical records from participants that visited a health care provider were scrutinized. This study 
involved 1769 tick-bitten participants. 
Our results indicate that the risk of contracting babesiosis after a tick bite is low, even if a 
Babesia-positive tick has been feeding for more than three days and contains up to 107 Babesia 
spp. genome copies per tick. Our findings of participants with positive serology indicate, 
however, that human infection with Babesia spp. with clinical symptoms occurs in Sweden and 
in the Åland Islands. Thus, babesiosis should not be neglected as a possible diagnosis in patients 
experiencing symptoms following a tick bite. 
We are convinced that the results of this study should be of great interest to many readers of 
Ticks and Tick-borne Diseases. We decided to submit this manuscript to Ticks and Tick-borne 
Diseases also because we consider this medical journal to be a highly appreciated scientific 
journal of excellent quality. 
Being the corresponding author, I – and on behalf of all the authors – hereby certify that this 
paper is an original work. No part of this manuscript has been published previously. All authors 
have seen and approved the final version of the manuscript.
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We would yet again like to thank the reviewers for the valuable comments on our 
manuscript TTBDIS_2018_332, which have helped us to further substantially improve the 
quality of the manuscript. We have tried to fulfill all requests and answer all of the 
questions and give feed-back on the comments raised by the reviewers. 
In this letter, point-by-point answers follow. The comments from the reviewers have been 
copied into this letter and formatted with the Calibri font and put in italics. Our answers 
follow after each comment in the Times New Roman font.
We hope that this will help with the final decision about the manuscript.
On behalf of all authors,
Matilda Lövmar
Enclosures:
1. The revised manuscript with figures
2. The two questionnaires used in the TBD-STING study, translated into English
Editor and Reviewer Comments:
  - Section editor:
Accept after tidying up the last problems as indicated by reviewer 4!
-Managing Editor
The questionable 2 paragraphs can stay in the paper.
Minor comments:
Abstract: Please, write out numbers at the beginning of sentences.
L109-110: These references need some copy editing. 
L161 (similar cases also elsewhere in the text): Borrelia-negative
L205: 36 h  [space missing]
L226: Twenty-nine
L227 (also elsewhere in the text): No double full stop.
L339: Nordström
L360-361: Please, use sentence case (no capitalisation of words) rather than title case.
L404: Bergström
L489: Nyström
All of the above mentioned comments have been corrected.
-Reviewer 1
  - All of the issues I had raised were already addressed in the previous revision. 
-Reviewer 2
  - 
-Reviewer 3
  - 
-Reviewer 4
  - 
Major Comments
Line 162: are the 106 controls made of ANY and ALL Babesia and Borrelia negative samples 
collected during the entire study period, and matched geographically? If not, the 
seroprevalence, as reported, would be meaningless.
We have changed the text slightly to clarify, see lines 157-160. The controls were chosen 
from all the Babesia- and Borrelia-negative ticks and geographically matched, twice as many 
controls were chosen as participants with positive ticks. 
Line 212: Figure 2B appears to indicate that the prevalence of B. venatorum infected ticks is 
HIGHER in southcentral Sweden when compared with Aland Islands. Here, the text indicates 
that the prevalence is HIGHER in the Aland Islands. Which is correct?  This comment also 
applies to the sentence on lines 243-244.
There is no figure 2B but we have assumed that the reviewers comment is regarding figure 
1B. We have changed the figure text slightly to make this clearer, the statement in the 
manuscript is correct regarding higher prevalence in the Åland Islands. See the new figure 
text for Fig 1B.
Minor Comments
Lines 3-4: the following title “Clinical/serological outcome in humans bitten by Babesia spp. 
positive Ixodes ricinus ticks in Sweden and on the Aland Islands” may be more attractive to 
the reader, in particular when browsing PubMed.
Thank you for this comment, we have changed the title accordingly.
Lines 36-37: change to “Sixty-five of 2098 ticks were positive (3.1%) by real-time PCR. Three 
Babesia species …”
Changed according to comment.
Line 39: change to “Half (46%) of the Babesia ….”
Changed according to comment.
Line 39: change to “Fifty-three participants …”
Changed according to comment.
Lines 44-47: change to “Given the prevalence of Babesia in I. ricinus ticks in southern Sweden 
and on the Aland Islands, babesiosis should be considered a possible diagnosis in 
symptomatic residents who seek medical care following tick exposure.”
Changed according to comment, we have also altered the conclusion where a similar phrasing 
was used, see lines 318-322. 
Line 53: change to “… transmitted by several tick …”
Changed according to comment.
Line 55: change to “The first documented case of …”
Changed according to comment.
Lines 56-57: change to “… was reported in 1957 from Yugoslavia (Skrabalo and Deanovic, 
1957). Other cases followed in Western Europe …”
Changed according to comment.
Line 65: change to “… include fever, malaise, chills, sweats, headache and myalgia …”
Changed according to comment.
Lines 71-73: Add to the citations the report by Moniusko-Malinowska et al. in Infectious 
Diseases vol 48, pp.537-543, 2016.
This reference has been added to the citations. 
Line 81: delete “In Sweden,”
Changed according to comment.
Line 84: delete “However,”
Changed according to comment.
Line 86: delete “previously”
Changed according to comment.
Line 87: modify to “Co-infection with Babesia and Borrelia spp. has been documented …”
Changed according to comment.
Line 90: delete the number 3, unless it means something.
Deleted according to comment.
Line 92: replace “intensified” with “worse”.
Changed according to comment.
Lines 96: delete this part of the sentence “relative to the ….. were used”, and use the edited 
sentence as the last sentence of the previous paragraph.’
We deleted the last part of one sentence according to this comment and moved the sentence 
to the previous paragraph. The last sentence of the paragraph was moved to the Material and 
Methods section. See lines 93-101.
Line 104: rephrase as “(PHCs) in the three regions of …”
Changed according to comment.
Line 114: delete “sera from”.
Changed according to comment.
Line 115: delete “serologically”.
Changed according to comment.
Line 116: delete “and analyzed for the presence of Babesia spp. using real-time PCR” because 
the current version of the manuscript no longer includes data on Babesia spp. detected by 
PCR in human blood samples.
Changed according to comment.
Lines 119-120: rephrase to “In this study, cDNAs from 2098 ticks detached from 1769 
participants were analyzed whereas cDNAs from the remaining 12 ticks were not available 
for analysis.”
Changed according to comment.
Lines 123-124: delete “, in total 5 uL cDNA per well.”
Changed according to comment.
Line 141: replace “Amplification” with “Extension”.
Changed according to comment.
Line 157: rephrase as “… from 53 of the 61 participants bitten by Babesia positive ticks were 
…”
Changed according to comment.
Line 165: start sentence as “Samples were …”.
Changed according to comment.
Line 182: replace with “Statistical Analysis”
Changed according to comment.
Lines 198-199: delete “, as compared with B. capreoli sequence (AY26009) deposited in 
Genebank,”. This info should be moved to the Methods section. 
We have left some of this information because it is a result from our study and as such should 
be presented in the results. Because of this comment we have rephrased it slightly, see lines 
193-196.
Lines 206-207: move the sentence “Different ticks …Babesia spp.” to after the next sentence.
Changed according to comment.
Lines 213-214: rephrase to “No other differences in species composition between regions 
were significant”.
Changed according to comment.
Line 224: rephrase to “Seven participants …”.
Changed according to comment.
Line 252: rephrase to “… in 0.6% of ticks (Jensen et al. 2017)”.
Changed according to comment.
Line 256: change to “…positive larvae among questing ticks, …”.
Changed according to comment.
Line 259: change to “… B. capreoli is known to be …”.
Changed according to comment.
Line 280: delete “on seroprevalence”
Changed according to comment.
Line 282: remove “antibodies”.
Changed according to comment.
STING-study Code ……………………… Date ……………………
1(4)
To participants of the STING-study
                                Please answer all questions!
When did you notice that you had been tick-bitten?
Year-Month-Day:    ________ ____ ____        Time ________
When do you think you were tick-bitten?
Year-Month-Day:    ________ ____ ____        Time ________
Where do you think you were when you were tick-bitten? Please state the 
name of the municipality.
_______________________________
What kind of habitat (vegetation type) had you visited?
Lake/Sea     Forest     Garden     Lawn     
Other:  ___________________________________________________
When was the tick removed?
Year-Month-Day:    ________ ____ ____         Time ________
Where on the body was the tick attached?   
_____________________________________
Did you remove the whole tick?         Yes     No    Do not know 
Have you had any other tick bites this season?    Yes     No    Do not know 
If Yes, how many?   1-4         5-9       >10 
STING-study Code ……………………… Date ……………………
2(4)
Have you ever been treated for the tick-borne infection Borrelia?
Yes     No     Do not know          If Yes; Year–Month–Day ________ ____ ____                           
 
Did you receive any medicine?
Yes     No     Do not know          If Yes; what kind of medicine did you get?               
           _______________________
               
Have you ever been treated for “Erythema migrans”? 
(Erythema migrans = red ring-like or homogenous expanding rash.)                          
Yes     No     Do not know          If Yes; Year–Month–Day ________ ____ ____                           
 
Did you then receive any medicine to treat the infection?
Yes     No     Do not know          If Yes; what kind?______________________
Have you ever been treated for the tick-borne infection “Ehrlichia” 
(= Ehrlichiosis, also called “Anaplasma” or anaplasmosis)?  
Yes     No     Do not know         If Yes; Year–Month–Day       ________ ____ ____                           
 
Did you receive any medicine to cure the Ehrlichia (Anaplasma) infection?
Yes     No     Do not know         If Yes; what kind?_________________________
STING-study Code ……………………… Date ……………………
3(4)
Have you ever been treated for the tick-borne infection TBE? 
(TBE is a viral disease which sometimes causes disease in the central nervous system.)
Yes     No     Do not know           If Yes; Year–Month–Day________ ____ ____                           
 
Did you receive any medicine?
Yes     No     Do not know           If Yes; what kind?________________________
Do you have any of the following diseases?
Asthma        Yes     No     Do not know   
Allergy        Yes     No     Do not know   
Diabetes    Yes     No     Do not know   
Tumour-related Yes     No     Do not know   
Are you on medication? Yes     No     
If Yes; what kind of medicine?
___________________________________________________________________
Do you smoke? Yes     No Stopped smoking   Year ________
If Yes, how many cigarettes per week? ________
How many years have you smoked? ________
STING-study Code ……………………… Date ……………………
4(4)
Do you have any pets?  Yes     No  
   
Dog         Yes     No     
Cat         Yes     No  
   
Bunny (rabbit)   Yes     No     
Other: _______________________________________________
Have you been vaccinated against TBE? Yes      No     Do not know        
If Yes; Year-Month-Day________ ____ ____
Have you been vaccinated against Yellow fever?  Yes      No     Do not know        
If Yes;   Year-Month-Day________ ____ ____
  
Have you been vaccinated against Japanese encephalitis? 
Yes      No     Do not know        
If Yes;   Year-Month-Day________ ____ ____
                                           
Thank you for your answers!
STING-study Code ……………………… Date …………………… 1(2)
Dear STING participant!
Three months have passed since you initiated your participation in the Tick-Borne 
Diseases STING-study. We previously received blood samples from you and a filled 
in questionnaire. Now, we need a follow-up blood sample. Therefore, you are 
requested to visit your primary health care centre at ____________________, 
week ___, Monday, Tuesday, Wednesday, or Thursday, between _____ and _____ 
a clock.
If you had any additional tick-bites since your study initiation and if you have 
collected the ticks in the tube with yellow cork, the please take that tube with you 
to the blood-sampling.
We would also like to know if you have had any symptoms related to tick-borne 
diseases during the study period. Please answer the following three questions and 
write your name, birth date and telephone number on the next page. We might 
contact you if you reported symptoms. Take this paper to your primary health care 
centre when you go for the sample-taking.
1) Have you had any additional tick-bites since the first sample-taking?
Yes     No     Do not know 
If Yes; when? Year-Month-Day: ________ ____ ____
2) How have you been feeling in general since the first sample-taking?
Have you been feeling good/as usual?
    
Yes     No     Do not know 
If No; please report if you had any of the following symptoms:
Headache Yes     No 
Fatigue Yes     No 
Fever, 38° or higher Yes     No 
Neck pain Yes     No 
Loss of appetite Yes     No 
Nausea Yes     No 
Weight loss Yes     No 
Vertigo Yes     No 
Concentration difficulties Yes     No 
Radiating pain Yes     No 
Muscle or joint pain Yes     No 
STING-study Code ……………………… Date …………………… 2(2)
Numbness Yes     No 
3) If you reported any symptoms in question 2, did the symptoms appear 
before or after any additional tick-bites?
Before additional tick-bite Yes     No     Do not know 
After additional tick-bite Yes     No     Do not know 
4) If you reported any symptoms in question 2, did you visit your primary 
health care centre due to the symptoms?
 Yes     No     
5) If you reported any symptoms in question 2, how many days did the 
symptoms last?
____________________
Thanks for your answers!
Please make sure you answered every question!
Bring this paper to your new sample-taking!
Name: ____________________________________________
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32 The risk of contracting babesiosis after a tick bite in Sweden and the Åland Islands, Finland, 
33 is unknown. We investigated clinical and serological outcomes in people bitten by Ixodes 
34 ricinus ticks positive for Babesia species. Ticks, blood and questionnaires were obtained 
35 from study participants in Sweden and on the Åland Islands. Sixty-five of 2098 (3.1%) ticks 
36 were positive by real-time PCR. Three Babesia species were detected, Babesia microti 
37 (n=33), B. venatorum (n=27) and B. capreoli (n=5), the latter species not known to cause 
38 human infection. Half (46%) of the Babesia PCR-positive ticks also contained Borrelia spp. 
39 Fifty-three participants bitten by a Babesia PCR-positive tick and a control group bitten by a 
40 Babesia PCR-negative tick were tested for B. microti IgG antibodies by IFA. The overall 
41 seroprevalence was 4.4%, but there was no significant difference between the groups. None 
42 of the participants seroconverted and no participant with a Babesia PCR-positive tick sought 
43 medical care or reported symptoms suggestive of babesiosis. Given the prevalence of Babesia 
44 in I. ricinus ticks in southern Sweden and on the Åland Islands, babesiosis should be 

































































49 Babesia; Babesiosis; Human; Seroconversion; Ixodes ricinus; Co-infection
50
51 INTRODUCTION
52 Human babesiosis is caused by parasites of the genus Babesia and transmitted by several tick 
53 species (Vannier and Krause, 2012). There are more than 100 known Babesia spp. that infect 
54 animals but only a few are known to infect humans. The first documented case of human 
55 babesiosis in Europe was reported in 1957 from Yugoslavia (Skrabalo and Deanovic, 1957). 
56 Other cases followed in Western Europe, including Scandinavia (Haapasalo et al., 2010; 
57 Morch et al., 2015) and a travel-associated case in Denmark (Holler et al., 2013). In Sweden 
58 there have been two reported cases of human babesiosis, both in splenectomized patients 
59 (Bläckberg et al., 2018; Uhnoo et al., 1992). In North America, babesiosis is considered an 
60 emerging health threat that is expanding into new geographical areas and may be overlooked 
61 by clinicians in regions not previously considered endemic (Gray and Herwaldt, 2019). Most 
62 cases in the United States have been reported in immunocompetent patients (Vannier et al., 
63 2015). The first case in the United States was reported in 1966 (Scholtens et al., 1968). 
64 Symptoms of babesiosis include fever, malaise, chills, sweats, headache and 
65 myalgia accompanied by anemia, leukopenia or leukocytosis, thrombocytopenia and elevated 
66 hepatic enzymes (Vannier and Krause, 2012). In Europe the most common cause of human 
67 babesiosis is Babesia divergens, which typically is diagnosed in immunocompromised 
68 individuals and gives rise to a severe illness (Vannier et al., 2015; Vannier and Krause, 2012). 
69 Infection with B. divergens has also been reported in immunocompetent patients (Martinot et 
70 al., 2011). A few cases of B. microti and B. venatorum infection have been reported in Europe 






























































72 Hildebrandt et al., 2007; Moniuszko-Malinowska et al., 2016). Infection with B. venatorum, 
73 giving mild to severe symptoms in splenectomized patients, has been reported (Haselbarth et 
74 al., 2007; Herwaldt et al., 2003). In the United States, B. microti is the most common causative 
75 agent of babesiosis; it causes mild to moderate symptoms and subclinical infections in 
76 immunocompetent persons (Vannier et al., 2015; Vannier and Krause, 2012). However, severe 
77 babesiosis may also occur, even in previously apparently healthy individuals (Gray and 
78 Herwaldt, 2019; Hatcher et al., 2001). 
79 In Sweden, the prevalence of Babesia spp. in questing I.  ricinus ticks was 
80 recently estimated to be 4.4% and included B. microti (3.2%), B. venatorum (1.0%) and B.  
81 divergens (0.2%) (Karlsson and Andersson, 2015). B. capreoli has been reported in roe deer, 
82 but this Babesia sp. is not known to cause human infections (Andersson et al., 2016; 
83 Malandrin et al., 2010). In Italy, the prevalence of B. venatorum in ticks that have bitten 
84 humans was estimated to be 0.6% (Otranto et al., 2014). To our knowledge, the clinical 
85 outcome and the rate of seroconversion after a bite by a Babesia containing tick or a tick co-
86 infected with Borrelia, have not been investigated. 
87 Co-infection with Babesia and Borrelia spp. has been documented several times 
88 (Diuk-Wasser et al., 2016; Knapp and Rice., 2015). There are differing opinions on the 
89 consequences of co-infection for severity of symptoms and prognosis in humans. According 
90 to Diuk-Wasser et al., (2016), the severity and duration of symptoms are greater in co-
91 infected patients and there are indications that co-infection may result in altered or 
92 suppressed immune response, which in turn leads to worse pathogenesis; more research is, 
93 however, needed. The aims of the present study were to investigate the prevalence of Babesia 
94 spp. in ticks that had bitten humans and to evaluate the concomitant risk of clinical babesiosis 






























































96 MATERIAL AND METHODS
97 TBD STING-study
98 Ticks, serum and questionnaires from the Tick-Borne Diseases (TBD) STING-study were 
99 used (Fryland et al., 2011; Grankvist et al., 2015; Henningsson et al., 2015; Henningsson et 
100 al., 2016; Lindblom et al., 2014; Wilhelmsson et al., 2010; Wilhelmsson et al., 2013a; 
101 Wilhelmsson et al., 2013b).
102 Ticks and blood samples were collected during 2008–2009 at 34 primary healthcare centers 
103 (PHCs) in the three regions of Sweden (Northern Sweden, South Central Sweden and 
104 Southernmost Sweden) and on the Åland Islands, Finland (Figure 1A). Only 
105 immunocompetent tick-bitten individuals ≥18 years were included. Questionnaires, ethical 
106 approval, collection, transport and storage of ticks and blood samples, determination of 
107 developmental stage and feeding time of ticks, and extraction and treatment of nucleic acids 
108 have been described previously (Andersson et al., 2016; Wilhelmsson et al., 2013a; 
109 Wilhelmsson et al., 2013b). Babesia spp. were detected using real-time PCR-based 
110 amplification of reverse-transcribed total nucleic acids. 
111  Blood samples were collected from participants within three days of the tick 
112 bite and three months later (Figure 2). Serum samples from participants with Babesia PCR-
113 positive ticks and a negative control group, consisting of participants bitten by a Babesia 
114 PCR-negative tick, geographically matched, were analyzed by IFA.  
115 Detection of Babesia spp. in ticks using SYBR-green real-time PCR assay 
116 A total of 2110 ticks detached from 1770 participants were delivered from PHCs during 
117 2008–2009. In this study, cDNAs from 2098 ticks detached from 1769 participants were 






























































119 The 2098 cDNA samples of the individually extracted ticks were grouped into 
120 pools of five, i.e. one μl of cDNA from each tick was used per well. Samples from the 
121 positive pools were individually analyzed using 2 μl cDNA. The PCR mixture contained 10 
122 μl SYBR-green (Thermo Scientific, Helsingborg, Sweden), 0.4 μl of each primer (10 µM), 
123 BJ1: 5´-GTC TTG TAA TTG GAA TGA TGG-3´ (Invitrogen™, Thermo Scientific) and 
124 BN2: 5´-TAG TTT ATG GTT AGG ACT ACG-3´ (Casati et al., 2006), 4.2 μl RNase free 
125 water. Primers BJ1 and BN2 were designed to target the Babesia 18S rRNA gene to amplify 
126 a 411 to 452 bp long amplicon depending on the species of Babesia. For species 
127 determination, sequencing of the amplicon was carried out (see below). As a positive control, 
128 2 μl B. microti DNA (~10 ng/μl), extracted from I. ricinus ticks collected in Slovakia (kindly 
129 provided by Dr Bronislava Víchová, through Dr Martin Andersson), and 2 μl of a synthetic 
130 plasmid preparation was used. The plasmid contained the target sequence of the SYBR green 
131 real-time PCR assay, spanning the nucleotides 467-955 of the B. divergens 18S rRNA gene 
132 (acc. no AJ439713), synthesized and cloned in a pUC57 vector (Genscript USA Inc, NJ). The 
133 non-template control consisted of 10.8 µl PCR mixture and 9.2 μl RNase free water.  The 
134 SYBR-green real-time PCR on Babesia were performed using C1000TM Thermal Cycler, 
135 CFX96TM system (BioRad Laboratories, Inc., Hercules, CA). The PCR run was initiated by a 
136 denaturation step at 94°C for 10 min followed by 35 cycles of denaturation at 94°C for 1 min, 
137 annealing at 55°C for 1 min and elongation at 72°C for 2 min. Extension was completed by a 
138 further step at 72°C for 5 min, and melt curve analysis was performed (Casati et al., 2006). 
139
140 Babesia spp. identification by sequencing  
141 Samples positive for Babesia spp. in the real-time PCR assay were sent to Macrogen Inc. 
142 (Amsterdam, the Netherlands) for nucleotide sequencing. The reactions were based on 






























































144 version 7.2.5 (Tom Hall, Ibis Therapeutics, Carlsbad, CA) and sequences examined using the 
145 Basic Local Alignment Tool (BLAST). Sequences obtained have been deposited in GenBank 
146 with accession numbers ranging from MH351680 to MH351744.                         
147 Species determination for B. microti and B. venatorum is possible by sequencing the 
148 amplicon from the real-time PCR assay. To fully distinguish between the two genetically 
149 similar Babesia spp., B. divergens and B. capreoli, three sets of primers were used to amplify 
150 and sequence the complete 18S rRNA gene from all samples positive for these species, as 
151 earlier described (Malandrin et al., 2010).
152 Detection of Babesia microti IgG antibodies in human serum
153 The first and second serum samples (collected at recruitment of participants and three months 
154 later, respectively) from 53 of the 61 participants bitten by Babesia-positive ticks were 
155 analyzed for the presence of B. microti IgG antibodies, using an indirect immunofluorescence 
156 assay (IFA); (Focus Diagnostics, Cypress, CA). For the remaining eight participants, serum 
157 was not available for analysis, since it had been used for other analyses. Twice as many 
158 controls were selected; first sample sera from participants bitten by Babesia- and Borrelia- 
159 negative ticks were matched geographically and used as controls (n=106) for analysis 
160 regarding IgG antibodies against B. microti. For B. venatorum there were no commercial kits 
161 available at the time of the study. IFA titers ≥1:64 were defined as positive. A cut-off value 
162 of 1:64 was used in accordance with previous research (Johnson et al., 2009). Samples were 
163 diluted to determine the highest positive titer. The IFA-slides were analyzed by two 
164 researchers independently, samples were defined as positive when both researchers found 
165 them positive. For the diagnosis of on-going or recent Babesia spp. infection, at least a four-
166 fold rise of the IFA titer (Krause, 2003; Vannier and Krause, 2012) was required when first 






























































168 Self-reported symptoms in the questionnaires of the TBD STING-study and medical 
169 records
170 The questionnaires from participants with Babesia PCR-positive ticks were scrutinized for 
171 symptoms suggestive of babesiosis, i.e. chills, fever, headache, nausea, myalgia, malaise, 
172 weight loss, arthralgia and lack of appetite (Vannier and Krause, 2012). Other symptoms 
173 indicating TBD in the questionnaires were neck pain, vertigo, concentration difficulties, 
174 numbness, radiating pain. If participants sought medical care during the three-month study 
175 period, the medical records were obtained and scrutinized for symptoms of babesiosis and/or 
176 if they were diagnosed with babesiosis or another TBD. 
177 Co-infection of tick-borne pathogens in ticks 
178 Borrelia-data from the TBD STING-study were used to determine which ticks were co-
179 infected with both Babesia spp. and Borrelia spp.  (Wilhelmsson et al., 2013a). 
180 Statistical analysis
181 The Chi square test was applied to compare prevalence of Babesia spp. between regions and 
182 between tick developmental stages, but when the expected frequency was < 5 in at least one 
183 of the cells of the contingency table, we used Fisher’s exact test. Statistical analyses were 
184 performed using GraphPad Prism version 6.04 for Windows (GraphPad Software, San Diego, 
185 CA). P-values <0.05 were considered significant.
186 RESULTS 
187 Babesia species in ticks detached from humans 
188 A total of 2098 ticks that had bitten humans were analyzed (Table 1). Sixty (2.9%) of the 
189 ticks were damaged to the extent that neither developmental stage nor the species could be 






























































191 (70%) nymphs, and 486 (23%) adults. 65 of 2098 ticks (3.1%) were positive for Babesia spp. 
192 by real-time PCR assay. Based on nucleotide sequencing of the PCR products, three Babesia 
193 species were detected; B. microti (n=33), B. venatorum (n=27), and B. capreoli (n=5). Our 
194 analysis of the complete 18S rDNA sequences for the five samples initially determined as 
195 either B. divergens or B. capreoli revealed a signature typical of B. capreoli at positions 631, 
196 663 and 1637 (GTT), as compared with B. capreoli sequence (GeneBank: AY26009). In our 
197 study there was no significant difference in Babesia prevalence between adult ticks and 
198 nymphs or between nymphs and larvae. However, the prevalence of B. microti was 
199 significantly higher in adult ticks than in nymphs (p<0.05). 
200  The 65 PCR-positive ticks were collected from 61 participants and the duration 
201 of tick feeding could be estimated for 58 of the 65 ticks (Appendix). 21 of these ticks had 
202 been feeding for > 36 h and the remaining 37 ticks < 36 h. There were three participants 
203 bitten by more than one infected tick. One participant from the Åland Islands was bitten by 
204 three infected ticks, one from Southcentral Sweden was bitten by two infected ticks, and one 
205 from Southernmost Sweden was bitten by two infected ticks (Appendix). Different ticks from 
206 the same participant contained different Babesia spp. There was no significant difference in 
207 prevalence of infected ticks between the geographic regions (Figure 1B). However, there was 
208 a significant difference in species composition of Babesia between the geographic regions, 
209 with B. venatorum more prevalent in the Åland Islands than in Southcentral Sweden 
210 (p<0.03). No other differences in species composition between the regions were significant.
211 Co-infection with Babesia spp. and Borrelia spp. in ticks 
212 To find which ticks contained Borrelia spp., data from the TBD STING-study were used 
213 (Wilhelmsson et al., 2013a). Thirty out of 65 (46%) Babesia spp. positive ticks contained 






























































215 involving B. microti and Borrelia spp. (60%) and the frequency of co-infections involving B. 
216 venatorum and Borrelia spp. (30%) (p<0.01). 
217 Seroprevalence, seroconversion and reported symptoms of the tick-bitten participants
218 The overall seroprevalence for B. microti was 7 out of 159 (4.4%) with no significant 
219 difference between the participants bitten by Babesia PCR-positive ticks and participants 
220 bitten by Babesia PCR-negative ticks. Seven participants were found seropositive both in 
221 first and second sample sera (Table 2). 
222 Twenty-nine participants were bitten by ticks containing both Babesia spp. and 
223 Borrelia spp. One of these participants was bitten by two ticks positive for Babesia spp. and 
224 Borrelia spp. Data regarding seroconversion for Borrelia spp. showed that one of the 
225 participants who seroconverted to Borrelia had a Babesia PCR-positive tick. However, this 
226 participant had a negative B. microti serology.
227  There were ten participants with Babesia PCR-positive ticks who reported 
228 symptoms in their questionnaires. The symptoms included headache, muscle pain, fatigue, 
229 neck pain, dizziness, concentration difficulties, numbness, radiating pain, joint pain and 
230 nausea. Only one of these participants had B. microti IgG antibodies. This participant sought 
231 medical care at the PHC during the study period but according to notes found in the medical 
232 records, symptoms were deemed not relevant to the tick bite. 
233 DISCUSSION
234 To our knowledge this is the first time Babesia has been found in ticks that have bitten 
235 humans in Sweden. In total, 3.1% of ticks collected from four regions in Sweden and in the 
236 Åland Islands contained Babesia spp. Babesia infected ticks were found in three of the four 
237 regions studied (Fig. 1B). A previous study on the prevalence of Babesia spp., in questing 






























































239 (Karlsson and Andersson, 2015). Comparing prevalence of Babesia spp. in the different 
240 regions, B. venatorum was more prevalent on the Åland Islands than in Southcentral Sweden. 
241 One could speculate the difference is related to different Babesia reservoir host composition.
242  We found that the most prevalent species in ticks collected from 
243 humans was B. microti, followed by B. venatorum and B. capreoli. In Sweden B. capreoli has 
244 been found in 44% of roe deer (Andersson et al., 2016), but this species is not known to cause 
245 human infections (Malandrin et al., 2010). We did not find any samples positive for B. 
246 divergens. A study conducted in Norway found that 0.1% of field-collected ticks are infected 
247 with B. divergens, 0.1% with B. capreoli and 0.6% with B. venatorum (Øines et al., 2012). In 
248 Denmark, B. divergens was found in 1.9% of ticks and B. venatorum in 0.6% of ticks (Jensen 
249 et al., 2017). Karlsson and Andersson (2015) found 0.2% questing ticks containing B. 
250 divergens in Sweden and found no significant difference in prevalence of Babesia spp. in 
251 adult ticks compared to nymphs. They found a higher prevalence in nymphs than in adults 
252 and they found no positive larvae among questing ticks, but we analyzed four times as many 
253 ticks and they were collected from humans. We found only one positive larva (Table 1) that 
254 contained B. capreoli. B. capreoli has not previously been found in larvae, however, B. 
255 divergens which is genetically similar to B. capreoli is known to be transovarially transmitted 
256 (Bonnet et al., 2007).  
257 Nearly one-half of the ticks positive for Babesia spp. were positive for Borrelia 
258 spp. Sixty percent of ticks containing B. microti were co-infected with Borrelia spp. 
259 compared to 30% of ticks containing B. venatorum. This may reflect the genus ratio of 
260 Babesia spp. and Borrelia spp. in reservoir hosts. It has been observed in an experimental 
261 model that mice co-infected with a strain of B. microti and an invasive strain of B. 






























































263 to mice infected with B. microti alone (Dunn et al., 2014). It remains to be confirmed if this 
264 finding applies to I. ricinus and one or several Babesia spp. it can transmit. 
265 Seven participants were positive for B. microti antibodies. Since 
266 none of them seroconverted and the antibody titers were low, we did not suspect an ongoing 
267 infection (Vannier and Krause, 2012). It is probable that they had a previous or subclinical 
268 infection and still carried antibodies. In a previous study, Lempereur et al. (2015) found no 
269 antibody cross-reactivity between B. microti and B. venatorum used as IFA antigens, but IgM 
270 cross reactivity between B. microti and B. divergens has been observed in another study 
271 (Haselbarth et al., 2007). Bläckberg et al. (2018) reported that a patient with B. venatorum-
272 infection had B. divergens IgG antibodies. For the participants with a positive B. microti 
273 serology, only three had been bitten by Babesia PCR-positive ticks during the study period. 
274 Because they had the same antibody titers in the first serum sample as in the second, it is not 
275 likely that the tick-bite during the study period was the cause of the positive serology or that 
276 the participants had an ongoing infection. One study in southern Sweden has revealed a 
277 prevalence of 16.3% for B. microti and B. divergens antibodies in a geographically selected 
278 cohort of seropositive Borrelia s.l. patients; and a 2.5% prevalence in a healthy control group 
279 (Svensson et al., 2019).  However, comparing this study to ours is complicated, since we have 
280 used another serological assay for Babesia antibodies and the study populations differ from 
281 each other.
282 In total, three participants were bitten by more than one Babesia PCR-positive 
283 tick, none of them developed antibodies against B. microti during the study period. One of 
284 these participants was bitten by ticks containing B. capreoli, not confirmed to be human 
285 pathogenic. Since we only analyzed for B. microti IgG we cannot draw any general 
286 conclusions regarding Babesia spp. antibodies. However, it is an interesting future 






























































288 their questionnaires or sought medical care during the study period. This suggests a low risk 
289 of transmission despite being bitten by several positive ticks and different species. 
290 Furthermore, the efficacy of transmission has been shown to correlate with the duration of 
291 tick feeding (for I. scapularis) in hamsters and white-footed mice, with infection rates close 
292 to 100% if the tick is allowed to feed to repletion (Piesman and Spielman, 1980). However, it 
293 is not known if this is true for I. ricinus and/or human hosts. In our study ticks were removed 
294 by the participant before repletion. 
295  Ten participants with Babesia PCR-positive ticks reported symptoms in their 
296 questionnaires. These symptoms were nonspecific and might indicate different conditions, 
297 babesiosis included. Only one participant bitten by a Babesia PCR-positive tick sought 
298 medical care during the study period. According to medical records, symptoms were 
299 unrelated to the tick bite. Thus, we conclude that none of the participants suffered from 
300 symptoms of babesiosis.
301  Twenty-nine of 61 participants with Babesia PCR-positive ticks were bitten by 
302 ticks co-infected with Borrelia. Of the ten participants who reported symptoms, five had been 
303 bitten by ticks positive for both Babesia spp. and Borrelia spp. The symptoms reported could 
304 be attributed either to babesiosis, borreliosis or other infections. None of the participants who 
305 reported symptoms, with the exception of the participant mentioned above, had sought 
306 medical care. This suggests that no participant suffered from severe illness.
307 One of the potential limitations of this study is that we did not test the serum for 
308 B. venatorum antibodies since we did not have available commercial kits for these analyses. 
309 The conclusions that can be drawn from the serological analyses are further limited by the 
310 lack of information regarding travel history, since this was not included in the questionnaires, 
311 designed for the TBD STING-study. Unfortunately, whole blood samples from the TBD 































































314 In conclusion our results indicate that immunocompetent individuals have a low risk of 
315 developing severe babesiosis after an I. ricinus tick bite in Sweden and on the Åland Islands, 
316 particularly when the tick has been feeding for less than 36 hours. Our findings of 
317 participants with positive serology suggests that human infection with B. microti occurs in 
318 Sweden, although we do not know about the travel history of these participants. Given the 
319 prevalence of Babesia in I. ricinus ticks as well as the seroprevalence of Babesia antibodies 
320 among residents in southern Sweden and on the Åland Islands, babesiosis should be 
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517 Table 1. Analyzed ticks and distribution of developmental stages.
Developmental 
stage of the tick 
Total no. of 
ticks analyzed
No. of Babesia 
PCR-positive 
ticks (%)
No. of ticks PCR-
positive for B. 
microti 
No. of ticks PCR-
positive for B. 
venatorum
No. of ticks PCR-














Nymphs 1466 43 (2.9) 20 20 3
Larvae 86 1 (1.2) 0 0 1
ND* 60 0 (0) 0 0 0
Total 2098 65 (3.1) 33 27 5
518 *Developmental stage could not be determined due to damaged tick
519
520 Table 2. B. microti IgG antibody titers for samples positive in the serological analysis (n=7).
Participant 
Id. code. *
Antibody titers in 
1st  sample‡
Antibody titers in 
2nd sample‡







Afa 89 1:128 1:128 B. venatorum 25 N
Vofa 15 1:256 1:256 B. microti 35 A
Vifa 25 1:64 1:64 B. microti <24 A
†Kafa 6 1:256 1:256 Neg. <24 N
†Kafa 52 1:64 1:64 Neg. 25 N
†Kfa 11 1:128 1:64 Neg. ND¶ N
†Kfa 13 1:64 1:64 Neg. <24 A
521
522 *Participant Id. code. Letters representing primary healthcare center where tick was collected followed by serial number.
523 †Sample from control group
524 ‡1st sample collected at inclusion, 2nd sample after three months
525 § Babesia spp. found in the tick collected at inclusion
526 ¶ ND = not determined due to deformed tick, making scutal and coxal indices impossible to determine

































































531 Figure 1. A. Map, showing the four regions (Northern Sweden, South Central Sweden, 
532 Southernmost Sweden, Åland Islands) where the 34 primary health care centers (PHCs, black 
533 dots) are located. B. Map showing PHCs where ticks positive for different Babesia species 
534 were collected, Babesia microti (red circles), Babesia venatorum (black crosses) and Babesia 
535 capreoli (filled green circles). Numbers (X/Y) next to region showing number of positive 
536 ticks in each region (X) with total number of ticks collected (Y). Maps modified from 
537 Wilhelmsson et al. 2013b. 
538 Figure 2. Flow-chart showing the study design and methods. Green for information regarding 
539 ticks, red for blood samples and blue for questionnaires. 
540 *Excluded because no samples were available, they had been used for previous analyses.
541 † Excluded since sera were not available, it had been used for previous analyses.
542 ‡ Denoted as the negative control group.
543








Babesia spp. in 
the tick 
Borrelia 





Åland Islands Afa 22 A <24 B. microti B. afzelii 3.3 x 102
Afa 89 N 25 B. venatorum B. afzelii 3.1 x 103
Afa 
115B*
N <24 B. venatorum
Afa 132B N 46 B. venatorum ND‡ 1
Afa 132C N <24 B. microti
Afa 132D A 30 B. venatorum
Afa 144 N 50 B. venatorum
Afa 156A A(male) -† B. venatorum
Afa 178 N 42 B. venatorum
Afa 185 A - B. microti
Afa 190 N <24 B. venatorum B. afzelii 2.3 x 104
Afa 217 A <24 B. microti B. afzelii 1.6 x 104
Afa 237 A 34 B. venatorum
Afa 338 A <24 B. microti
Afa 350 N <24 B. microti B. afzelii 1.1 x 104
Afa 380 N 51 B. capreoli
Afa 381 N 30 B. microti
Afa 412 N 45 B. venatorum
Afa 465 N <24 B. venatorum
Afa 466 N 42 B. venatorum B. afzelii 6.7 x 104
Afa 476 N <24 B. microti B. afzelii 5.3 x 104
Afa 498D N <24 B. venatorum
Afa 499 N <24 B. venatorum
Afa 518A N <24 B. microti
Afa 537 N <24 B. venatorum
Afa 560 N <24 B. microti


































































Bafa 6 A <24 B. microti B. afzelii 3.4 x 102
Bafa 73A A <24 B. microti





Ekfa 84 A - B. microti B. afzelii 2.7 x 104
Grfa 28 N 56 B. microti B. garinii 1.3 x 103
Hafa 8 N <24 B. venatorum
Hafa 16 N 25 B. microti B. afzelii 3.1 x 104
Hafa 44B A <24 B. venatorum B. 
miyamotoi
1.9 x 106
Hafa 115 A 61 B. venatorum B. afzelii 1.7 x 101
Jofa 7 N 47 B. microti B. afzelii 6.3 x 102
Lidfa 14 N 55 B. venatorum B. garinii 1.4x 103
Lidfa 30 A <24 B. microti ND 1.1 x 102
Lidfa 39A L - B. capreoli
Lidfa 39B N 52 B. capreoli
Lidfa 46 N 26 B. venatorum
Lidfa 92B N <24 B. microti B. afzelii 3.9 x 104
Mekfa 16 A - B. venatorum
Sofa 76 A 166 B. microti ND 1.1 x 102
Vvfa 66 A - B. microti
Vifa 20 N 70 B. microti
Vifa 25 A <24 B. microti B. afzelii 1.9 x 105
Southernmost 
Sweden
Blefa 13 N <24 B. microti B. afzelii 7.9 x 103
Blefa 19 N 37 B. microti
Blefa 
38B
N <24 B. microti B. afzelii 8.8 x 103
Blefa 
38D
N <24 B. venatorum B. afzelii 9.5 x 102
Kafa 7 N 57 B. venatorum
Kafa 34 N 59 B. venatorum
Kafa 36 N <24 B. microti B. afzelii 3.5 x 103
Kafa 75 N 49 B. microti
Kafa 84A N 60 B. microti B. afzelii 7.0 x 101
Kafa 
100A
N 25 B. microti B. afzelii 1.8 x 104
Kfa 9 N <24 B. venatorum
Kfa 18 N - B. venatorum
Kfa 25 N 37 B. capreoli
Lafa 13 A 51 B. venatorum
Ofa 15C N 35 B. microti B. afzelii 1.4 x 104
Vofa 15 A 35 B. microti
Ysfa 9 A 38 B. microti B. afzelii 1.5 x 101
545 *Letter after Id. Code for participants who turned in more than one tick to the PHC, the first tick XXfaA, the second XXfaB etc. 
546 †Feeding time could not be determined 
547 ‡ND = Species could not be determined
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